Ge 2009.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Location: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 80. Age: 18～40 years, aripiprazole group: mean = (22.1 ± 5.9) years; quetiapine group: mean = (24.8 ± 7.2) years. Gender: Not reported. History: aripiprazole group: mean = (1.1 ± 0.7) years; quetiapine group: mean = (1.3 ± 0.7) years. Age at onset not reported.
Interventions	1. Aripiprazole: Initial dose: 5 mg/day. Mean = (25.5 ± 1.8) mg/day. N = 40. 2. Quetiapine: Initial dose: 100mg/day. Mean = (425 ± 27) mg/day. N = 40.
Outcomes	Mental state: PANSS total score. PANSS positive subscale score, PANSS negative subscale score, PANSS general psychogenic pathological subscale score. Adverse effects.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear if there were incomplete data.
Selective reporting (reporting bias)	High risk	Although TESS was used to assess adverse effects, no data on score were available.
Other bias	Low risk	None obvious.